Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

Nature Medicine

Volumn 4, Issue 3, 1998, Pages 321-327

  Rosenberg, Steven A ^a   Yang, James C ^a   Schwartzentruber, Douglas J ^a   Hwu, Patrick ^a   Marincola, Francesco M ^a   Topalian, Suzanne L ^a   Restifo, Nicholas P ^a   Dudley, Mark E ^a   Schwarz, Susan L ^a   Spiess, Paul J ^a   Wunderlich, John R ^a   Parkhurst, Maria R ^a   Kawakami, Yutaka ^a   Seipp, Claudia A ^a   Einhorn, Jan H ^a   White, Donald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; INTERLEUKIN 2; MELANOMA VACCINE; SYNTHETIC PEPTIDE;

ADULT; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINE PRODUCTION;

ADULT; CANCER VACCINES; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FEMALE; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; INTERLEUKIN-2; LUNG NEOPLASMS; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS;

EID: 0031890206     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0398-321     Document Type: Article

References (38)

1. Rosenberg, S.A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am. 1, 89-100 (1995).
2. Boon, T. Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy. Int. J. Cancer 54, 177-180 (1993).
3. Rosenberg, S.A. et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: Preliminary report. N. Engl. J. Med. 319, 1676-1680 (1988).
4. Rosenberg, S.A. et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86, 1159-1166 (1994).
5. Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91, 6458-6462 (1994).
6. Kawakami, Y. et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515-3519 (1994).
7. Kawakami, Y. et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med, 180, 347-352 (1994).
8. Kawakami, Y. et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3461-3968 (1995).
9. Parkhurst, MR. et al. Improved induction of melanoma reactive CTLs with peptides from the melanoma antigen gp100 modified at HLA-A*0210 binding residues. J. Immunol. 157, 2537-2548 (1996).
10. Rivoltini, L. et al. Induction of tumor-reactive CTLs from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 54, 2257-2265 (1995).
11. Salgaller, M.L. et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55, 4972-4979 (1995).
12. Marincola, F.M., Rivoltini, L., Salgaller, M.L., Player, M., & Rosenberg, S.A. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence for in vivo priming by tumor cells. J. Immunother. 19, 266-277 (1996).
13. Cormier, J.N. et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. USA 3, 37-44 (1996).
14. Salgaller, M.L., Marincola, F.M., Cormier, J.N., & Rosenberg, S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56, 4749-4757 (1996).
15. Aichele, P., Hengartner, H., Zinkergnagel R.M., & Schulz, M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 171, 815-1820 (1990).
16. Kast, W.M., et al. Protection against lethal sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88, 2283-2287 (1991).
17. Celluzzi, C.M., Mayorodomo, J.I., Storkus, W.J., Lotze, M.T., & Falo, L.D. Peptidepulsed dendritic cells induced antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283-287 (1996).
18. Mandelboim O. et al. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369, 67-71 (1994).
19. Deres, K., Schild, H., Wiesmuller, K-H., Jung, G., & Rammensee, H-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopetide vaccine. Nature 342, 561-564 (1989).
20. Lasarte, J-J., Sarobe, P., Gullon, A., Prieto, J., & Borras-Cuesta, F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-Helper synthetic peptide construct. Cell Immunol. 141, 211-218 (1992).
21. + CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549-556 (1994).
22. + T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54, 4155-4161 (1994).
23. Noguchi, Y., Richards, E.C., Chen, Y.T., & Old, L.J. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92, 2219-2223 (1995).
24. Kyburz D. et al. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23, 1956-1962 (1993).
25. Hu, X. et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56, 2479-2483 (1996).
26. Jaeger, E. et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66, 162-169 (1996).
27. Jaeger, E. et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67, 54-62 (1996).
28. Marchand, M. et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [Letter to the Editor]. Int. J. Cancer 63, 883-885 (1995).
29. Rosenberg, S.A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271, 907-913 (1994).
30. Coulie, P. et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50, 289-297 (1992).
31. Mazzocchi, A. et al. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int. J. Cancer 58, 330-339 (1994).
32. Herr, W., Wolfel, T., Heike, M., Meyer zun Buschenfelde, K-H., & Knuth, A. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol. Immunother. 39, 93-99 (1994).
33. Sharrock, C.E.M., Kaminski, E., & Man, S. Limiting dilution analysis of human T cells: A useful clinical tool. Immunol. Today 11, 281-286 (1990).
34. Gomez, I.B.A., Gomard, E., & Levy, J.P. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. Clin. Exp. Immunol. 84, 501-507 (1991).
35. + T cells. J. Immunol. 150, 2346-2355 (1993).
36. Bronte, V. et al. IL-2 enhances the function of recombtnant proxvirus- based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154, 4282-5292 (1995).
37. Irvine, K.R., Roa, R.B., Rosenberg, S.A., & Restifo, NP. Cytokine enhancement of DMA immunization leads to treatment of established pulmonary metastases. J. Immunol. 156, 238-245 (1996).
38. Rao, J.B. et al. Interleukin-12 is an effective adjuvant to recombinant vaccinia virus based tumor vaccines. J. Immunol. 156, 3357-3365 (1996).